Trial Profile
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs AMXT-1501 (Primary) ; Eflornithine (Primary)
- Indications Malignant-mesothelioma; Solid tumours
- Focus Adverse reactions
- Sponsors Aminex Therapeutics
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2023.
- 12 Aug 2022 Status changed from recruiting to active, no longer recruiting.